Advertisement
Business
Subscribe to Business

The Lead

BMS Second Quarter Net Drops on Lower Drug Sales, Charges

July 24, 2014 8:15 am | News | Comments

Bristol-Myers Squibb Co.'s exit from the diabetes business, plus higher taxes and research spending, combined to slash the drugmaker's second-quarter profit by 38 percent, but the company handily beat Wall Street's muted profit expectations.

Lilly Second Quarter Profit Falls 39%

July 24, 2014 7:31 am | by The Associated Press | News | Comments

Eli Lilly and Co. (LLY) on Thursday reported profit that declined by 39 percent in its second...

Roche Posts Seven Percent Profit Drop

July 24, 2014 2:29 am | by The Associated Press | News | Comments

Swiss drugmaker Roche Holding AG on Thursday posted a net profit drop of 7 percent compared with...

When Will We Learn?

July 23, 2014 3:11 pm | by Mike Auerbach, Editor In Chief | Blogs | Comments

Humans are a strange lot. We are more than willing to believe just about any product claim in...

View Sample

FREE Email Newsletter

Biogen Idec Second Quarter 2014 Revenues Increase 40%

July 23, 2014 9:18 am | News | Comments

Biogen Idec today reported second quarter 2014 results, including revenue of $2.4 billion, a 40% increase compared to the second quarter of 2013. Second quarter 2014 non-GAAP diluted earnings per share (EPS) were $3.49, an increase of 52% over the second quarter of 2013.

GSK's CEO and CFO Discuss the Company's Second Quarter Results

July 23, 2014 9:13 am | Videos | Comments

GSK CEO Sir Andrew Witty and CFO Simon Dingemans on the group’s Q2 2014 results and strategy update.                         

Shire Enters Strategic Licensing and Collaboration Agreement with ArmaGen

July 23, 2014 8:02 am | News | Comments

Shire and ArmaGen announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy (ERT) for the potential treatment of both the central nervous system (CNS) and somatic manifestations in patients with Hunter syndrome (MPS II).

Advertisement

How Inversion Deals Help Drug Makers Save on Taxes

July 22, 2014 8:59 am | Videos | Comments

Drug companies and medical device makers are making multi-billion-dollar merger deals to avoid high U.S. corporate taxes. How do so-called "inversion deals" work?               

MedImmune and Advaxis Partner on Immuno-Oncology Combination Clinical Trial

July 22, 2014 8:20 am | News | Comments

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies.    

J&J Buying Back $5B Worth of its Shares

July 21, 2014 6:26 pm | by The Associated Press | News | Comments

Johnson & Johnson, the world's biggest maker of health care products, plans to buy back up to $5 billion of the company's common stock. The maker of prescription drugs, medical devices and Tylenol said Monday that its board of directors had approved the stock buyback program.

Allergan Reports Second Quarter 2014 Operating Results; Announces Layoffs

July 21, 2014 8:45 am | News | Comments

Allergan, Inc. announced operating results for the quarter ended June 30, 2014 and announced a restructuring that will eliminate 1500 jobs.                   

States Sue 5-Hour Energy Over Ad Claims

July 21, 2014 8:35 am | by STEVEN DUBOIS, Associated Press | News | Comments

The Oregon lawsuit filed Thursday in Portland contends 5-Hour Energy falsely claims customers get extra energy and focus from a unique blend of ingredients, when the boost actually comes from a concentrated dose of caffeine.     

Advertisement

Valeant Takes Allergan Complaints to Regulators

July 21, 2014 8:23 am | by The Associated Press | News | Comments

Valeant Pharmaceuticals International Inc. is complaining to regulators that Botox maker and acquisition target Allergan has been making false statements about its business.             

Teva Completes Acquisition of Labrys

July 21, 2014 8:15 am | News | Comments

The acquisition of Labrys brings to Teva LBR-101, a fully humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), which is currently in Phase IIb clinical trials for prevention of chronic and episodic migraine.  

Arena Pharmaceuticals to Market and Supply BELVIQ in Israel

July 21, 2014 8:12 am | News | Comments

Arena Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into an exclusive marketing and supply agreement for BELVIQ with Teva Pharmaceutical Industries Limited's local Israeli subsidiary, Abic Marketing Limited.

GTCR to Acquire Cole-Parmer Instrument Company

July 17, 2014 1:55 pm | News | Comments

GTCR, a private equity firm, has entered into a definitive agreement to acquire the Cole-Parmer Instrument Company from Thermo Fisher Scientific Inc. for $480 million. Cole-Parmer, headquartered in Vernon Hills, Illinois, is a global manufacturer and distributor of specialty laboratory equipment, instruments and supplies to a diverse range of industries.

Novartis Cites Momentum in 3% Profit Rise

July 17, 2014 2:30 am | by The Associated Press | News | Comments

Novartis AG says its second-quarter profit rose 3 percent from a year earlier, reflecting solid growth and an increased focus on core products. The Basel-based company reports that profit during the April-June quarter rose to $3.28 billion, up from $3.18 billion in the same quarter of 2013.

Advertisement

Merz North America to Establish Headquarters in Raleigh, North Carolina

July 16, 2014 3:42 pm | News | Comments

Merz North America will establish its headquarters in Raleigh, North Carolina, officials announced today at a press conference with Gov. Pat McCrory. The global pharmaceutical company – part of the Merz Pharma Group, with affiliates in 18 countries around the world – will move operations from current headquarters in Greensboro and from elsewhere in the U.S.

Like Peanut Butter and Chocolate

July 16, 2014 3:02 pm | by Mike Auerbach, Editor In Chief | Blogs | Comments

Some things just seem to naturally go together – peanut butter and chocolate is one of those combinations – especially in the form of peanut butter cups. Bacon and eggs is another, as is peanut butter and jelly, pizza and beer and numerous other tasty combinations.

Aptuit Names Executive VP, Business Development & Marketing; Enhances Sterile Drug Product Capabilities

July 16, 2014 11:33 am | News | Comments

Aptuit LLC has appointed Paul D. Overton, Ph.D., as Executive Vice President, Business Development and Marketing, making him responsible for all of Aptuit’s sales and marketing activities.           

Strides Arcolab Makes Investments in Oncobiologics

July 16, 2014 11:28 am | News | Comments

The investment is part of Strides' strategy to fund promising biopharma companies with high quality scientific management and proprietary approaches to developments that confer significant time and cost advantages.      

Abbott Second Quarter Profit Falls on Higher Taxes, Revenue Up

July 16, 2014 9:37 am | News | Comments

Abbott Laboratories said that its second-quarter profit declined 2.1 percent, hampered by higher taxes. Adjusted profit and revenue topped Wall Street expectations, however, and the company boosted its full-year earnings forecast.    

Pfizer to Acquire InnoPharma

July 16, 2014 9:34 am | News | Comments

Pfizer and InnoPharma, a privately held pharmaceutical development company, today announced that they have entered into an agreement under which Pfizer will acquire InnoPharma. Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments.

GSK and Theravance Initiate Phase III Program for COPD Treatment

July 16, 2014 8:53 am | News | Comments

GlaxoSmithKline and Theravance today announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the 'closed' triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease (COPD).

West Dedicates Pharmaceutical Manufacturing Plant in India

July 16, 2014 8:41 am | News | Comments

In June 2012, West signed a 99-year lease on 72,800 square meters (approximately 783,600 square feet) of land in Sri City. Sri City offers the advantages of a metropolitan location and was selected primarily on the suitability of land, availability of utilities, labor suitability, logistics and quality of life.

Chiltern Acquires Ockham - Companies Merge Operations

July 15, 2014 11:45 am | News | Comments

Chiltern and Ockham, two full-service contract research organizations (CROs), today announce that Chiltern has acquired 100% of Ockham and that the companies will merge their operations. The combined company will be called Chiltern. Ockham's management team will join the management of the enlarged group, thus ensuring a seamless continuation of high quality services.

Bayer Names U.S. Head of Litigation

July 15, 2014 11:28 am | News | Comments

Bayer today announced the appointment of Malini Moorthy as Head of the Litigation Department in the United States, effective July 30.  She succeeds Kaspar Stoffelmayr, whose three-year assignment ended and has rejoined Bartlit Beck Herman Palenchar & Scott LLP.

Anthera Pharmaceuticals Acquires Sollpur for Exocrine Pancreatic Insufficiency From Eli Lilly

July 15, 2014 9:04 am | News | Comments

Sollpura is a soluble, stable and non-porcine enzyme product intended for the treatment of patients with low digestive enzyme levels, or Exocrine Pancreatic Insufficiency (EPI), due to cystic fibrosis, and potentially other diseases.   

LEO Pharma and KLOX Technologies Strike Global Dermatology Deal

July 15, 2014 8:57 am | News | Comments

LEO Pharma and KLOX Technologies Inc. have entered into a worldwide license and joint venture agreement, excluding Canada, to further develop and commercialize KLOX's BioPhotonic technology platform in dermatology, which includes a CE approved treatment for moderate to severe acne. 

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading